Literature DB >> 16822723

Type-2 diabetes mellitus related cardiovascular risk: new options for interventions to reduce risk and treatment goals.

F D Richard Hobbs1.   

Abstract

Diabetes represents a state of accelerated cardiovascular risk with data from longitudinal studies suggesting that in patients with well established diabetes the risk is equivalent to those with existing cardiovascular disease. In addition, the prognosis of patients with diabetes who suffer cardiovascular disease (CVD) is much worse. There are therefore dual imperatives for all physicians, particularly those in primary care, to focus on strategies to reduce vascular risk in their patients with diabetes. There are, in parallel, background issues that make this risk modification in diabetes a priority, with the rising prevalence of disease, driven at least in part by the rising tide of obesity, and the rising cost (42% of total expenditure) of treating CVD in diabetics. Evidence for interventions that modify the CVD risk in diabetes is now strong, with unequivocal data to support multifactorial risk modification, particularly for the effective targeting of glycaemia and blood pressure (with primary evidence for bp targets below standard care) from studies such as Steno2 and UKPDS, and lipid modification through the use of statins in both secondary (HPS) and primary (CARDS) prevention of CVD in diabetes. Knowledge of these interventions is high in primary care, but implementation is variable. This is probably at least in part because primary care physicians appear to consider risk factor modification within single risk strategies, rather than adopting lifestyle and therapeutic interventions that influence multiple risks in a systematic package of care and patient follow up.

Entities:  

Mesh:

Year:  2006        PMID: 16822723     DOI: 10.1016/j.atherosclerosissup.2006.05.005

Source DB:  PubMed          Journal:  Atheroscler Suppl        ISSN: 1567-5688            Impact factor:   3.235


  5 in total

Review 1.  Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms.

Authors:  Alin Stirban; Thomas Gawlowski; Michael Roden
Journal:  Mol Metab       Date:  2013-12-07       Impact factor: 7.422

2.  Cardiovascular disease in type 2 diabetes: Attributable risk due to modifiable risk factors.

Authors:  John Zeber; Michael L Parchman
Journal:  Can Fam Physician       Date:  2010-08       Impact factor: 3.275

3.  Increasing glucose concentrations and prevalence of diabetes mellitus in northern Sweden, 1990-2007.

Authors:  Bernt Lindahl; Hans Stenlund; Margareta Norberg
Journal:  Glob Health Action       Date:  2010-10-27       Impact factor: 2.640

4.  GLP-1-dependent and independent effects and molecular mechanisms of a dipeptidyl peptidase 4 inhibitor in vascular endothelial cells.

Authors:  Yunshan Hu; Hu Y; HongBin Liu; Liu Hb; Richard W Simpson; Simpson Rw; Anthony E Dear; Dear Ae
Journal:  Mol Biol Rep       Date:  2012-11-28       Impact factor: 2.316

Review 5.  Vascular Effects of Dietary Advanced Glycation End Products.

Authors:  Alin Stirban; Diethelm Tschöpe
Journal:  Int J Endocrinol       Date:  2015-05-18       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.